Roche taps Simcere for autoimmune trispecific for $1.53bn
Roche is paying $75 million for a trispecific antibody developed by a subsidiary of China's Simcere Pharma as a treatment for B-cell-mediated autoimmune disorders and blood cancers.
The deal with Nanjing-based Simcere Zaiming – which could swell to a value of $1.53 million with potential future milestone payments – gives Roche exclusive global rights to SIM0660, a trispecific antibody targeting CD79a, CD19, and CD3, which is currently in preclinical development.
Simcere Zaiming is also eligible to receive tiered royalties of up to double digits on net sales if it reaches the market.
SIM0660 was developed using Simcere Zaiming's T-cell engager (TCE) polyspecific antibody technology platform, which the company says generates molecules with a low-affinity/high-targeting activation CD3 engagement arm.
This design triggers robust T-cell cytotoxicity against pathological cells, while minimising the risk of systemic side effects, such as cytokine release syndrome (CRS).
"With its potential first-in-class dual-targeting approach to CD79a and CD19, SIM0660 is designed to provide broad coverage across B-cell-mediated diseases, and may offer a differentiated therapeutic approach for patients previously treated with CD20- or CD19-directed therapies," said the Chinese firm in a statement.
"In addition, SIM0660 also has therapeutic potential for B-cell-mediated autoimmune diseases, where targeted depletion of pathogenic B cells may provide clinical benefit."
Roche's business development chief, Boris Zaïtra, said the agreement with Simcere Zaiming "reflects our commitment to partnering with innovative companies to advance and deliver new therapeutic options for patients in need."
Simcere Pharma said the deal is its sixth out-licensing agreement, collectively worth up to $6.1 billion, which is further testament to the emerging importance of China as a source of new drug candidates for multinational pharma groups.
In 2025, Chinese-origin drug candidates accounted for approximately 30% of the global innovative pharmaceutical pipeline, which is nearly double Europe's share and approaching the US share, according to a recent paper in the journal eClinicalMedicine.
Other licensing deals signed by Simcere in the last few years include a $1.26 billion alliance with Boehringer Ingelheim for an anti-TL1AxIL-23 bispecific antibody for inflammatory bowel disease, a $1.06 billion agreement with Ipsen for an anti-LRRC15 antibody-drug conjugate (ADC) for solid tumours, and a $1.055 billion partnership, focusing on a GPRC5D/BCMA/CD3 trispecific antibody for multiple myeloma, with AbbVie.
The company also has a $745 million strategic alliance with NextCure for an ADC targeting cadherin-6 for platinum-resistant ovarian cancer (PROC).
